Construction and validation of a clinicopathologic signature for predicting the prognosis of stage II and III colorectal cancer

<h2>Abstract</h2><h3>Background</h3> Various clinical and pathological indicators affect the prognosis of stage II and III colorectal cancer (CRC). Nevertheless, few studies have systematically integrated these indicators to construct a signature for assessing the prognostic risk. <h3>Methods</h3> Patients with stage II-III CRC who underwent R0 radical resection from 2009 to 2016 were included in this study. All clinical and follow-up data were collected. Our study mainly incorporated an internal training cohort and an external validation cohort from two centers. Data processing and data analysis were performed in the R language. Cox proportional hazard regression was used for univariate and multivariable analyses. The log-rank test was performed to compare prognosis among groups. <h3>Findings</h3> A total of 1200 eligible patients were included in our study. 8 variables, including T, N stage, lymphatic/vascular infiltration, preoperative CEA, CA125, and CA199, were included and the nomogram was established in the signature for predicting OS. The concordance index of the signature was 0.72. The 3-year and 5-year calibration curves of CRC based on the nomogram showed a perfect correlation between predicted and observed outcomes. Obvious differences were observed in the survival of different risk groups (p < 0.001). Patients with a low-risk score signature had a 5-year OS rate of 77%, whereas patients with a high-risk score signature had the worst 5-year OS rate (only 8%). Furthermore, our signature also achieved similar performance in external cohort validation. <h3>Interpretation</h3> The signature based on clinical and pathologic factors had favorable accuracy for predicting the prognosis of stage II and III CRC. Therefore, our signature could identify high-risk patients with stage II and III CRC to guide adjuvant therapy and follow-up.

Authors

Publication Details

Journal
The Lancet Regional Health - Western Pacific
Published
2025-02-01
DOI
https://doi.org/10.1016/j.lanwpc.2024.101414
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Construction and validation of a clinicopathologic signature for predicting the prognosis of stage II and III colorectal cancer

Weiqiang You
The Lancet Regional Health - Western Pacific
Colorectal Cancer Treatments and Studies
article

Construction and validation of a clinicopathologic signature for predicting the prognosis of stage II and III colorectal cancer

Weiqiang You
article en

Abstract

<h2>Abstract</h2><h3>Background</h3> Various clinical and pathological indicators affect the prognosis of stage II and III colorectal cancer (CRC). Nevertheless, few studies have systematically integrated these indicators to construct a signature for assessing the prognostic risk. <h3>Methods</h3> Patients with stage II-III CRC who underwent R0 radical resection from 2009 to 2016 were included in this study. All clinical and follow-up data were collected. Our study mainly incorporated an internal training cohort and an external validation cohort from two centers. Data processing and data analysis were performed in the R language. Cox proportional hazard regression was used for univariate and multivariable analyses. The log-rank test was performed to compare prognosis among groups. <h3>Findings</h3> A total of 1200 eligible patients were included in our study. 8 variables, including T, N stage, lymphatic/vascular infiltration, preoperative CEA, CA125, and CA199, were included and the nomogram was established in the signature for predicting OS. The concordance index of the signature was 0.72. The 3-year and 5-year calibration curves of CRC based on the nomogram showed a perfect correlation between predicted and observed outcomes. Obvious differences were observed in the survival of different risk groups (p < 0.001). Patients with a low-risk score signature had a 5-year OS rate of 77%, whereas patients with a high-risk score signature had the worst 5-year OS rate (only 8%). Furthermore, our signature also achieved similar performance in external cohort validation. <h3>Interpretation</h3> The signature based on clinical and pathologic factors had favorable accuracy for predicting the prognosis of stage II and III CRC. Therefore, our signature could identify high-risk patients with stage II and III CRC to guide adjuvant therapy and follow-up.

The Lancet Regional Health - Western PacificVol. 55
Good health and well-being
Openalex Percentile: Top 96%
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.